Principal Financial Group Inc Heron Therapeutics, Inc. Transaction History

Principal Financial Group Inc

$172 Billion
Q4 2024

A detailed history of Principal Financial Group Inc transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 113,560 shares of HRTX stock, worth $210,086. This represents 0.0% of its overall portfolio holdings.

Number of Shares

113,560

Holding current value

$210,086

% of portfolio

0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 31, 2025	BUY	$1.06 - $2.12 $120,373 - $240,747	113,560 New	113,560 $173,000
Q3 2024 Oct 31, 2024	BUY	$1.73 - $3.67 $145,674 - $309,032	84,205 Added 456.49%	102,651 $204,000
Q2 2024 Jul 29, 2024	SELL	$2.32 - $3.86 $41,198 - $68,545	-17,758 Reduced 49.05%	18,446 $64,000
Q1 2024 Apr 29, 2024	SELL	$1.71 - $3.06 $1,203 - $2,154	-704 Reduced 1.91%	36,204 $100,000
Q4 2023 Feb 07, 2024	BUY	$0.54 - $1.82 $1,092 - $3,683	2,024 Added 5.8%	36,908 $62,000
Q3 2023 Nov 02, 2023	BUY	$0.97 - $1.8 $1,154 - $2,142	1,190 Added 3.53%	34,884 $35,000
Q2 2023 Aug 07, 2023	BUY	$1.11 - $2.88 $3,108 - $8,064	2,800 Added 9.06%	33,694 $39,000
Q1 2023 May 09, 2023	SELL	$1.51 - $3.25 $3,320 - $7,146	-2,199 Reduced 6.64%	30,894 $46,000
Q4 2022 Feb 09, 2023	BUY	$2.25 - $4.67 $14,269 - $29,617	6,342 Added 23.71%	33,093 $82,000
Q3 2022 Nov 09, 2022	SELL	$2.66 - $5.37 $1,686 - $3,404	-634 Reduced 2.32%	26,751 $113,000
Q2 2022 Aug 10, 2022	SELL	$2.3 - $6.29 $2,470 - $6,755	-1,074 Reduced 3.77%	27,385 $76,000
Q1 2022 May 09, 2022	BUY	$4.63 - $9.94 $2,560 - $5,496	553 Added 1.98%	28,459 $163,000
Q4 2021 Feb 09, 2022	SELL	$8.35 - $12.6 $80,393 - $121,312	-9,628 Reduced 25.65%	27,906 $254,000
Q3 2021 Nov 09, 2021	BUY	$10.13 - $15.0 $16,846 - $24,945	1,663 Added 4.64%	37,534 $401,000
Q2 2021 Aug 10, 2021	SELL	$13.27 - $18.48 $39,916 - $55,587	-3,008 Reduced 7.74%	35,871 $556,000
Q1 2021 May 10, 2021	SELL	$14.49 - $20.72 $30,052 - $42,973	-2,074 Reduced 5.06%	38,879 $630,000
Q4 2020 Feb 08, 2021	BUY	$14.61 - $22.14 $123,323 - $186,883	8,441 Added 25.96%	40,953 $867,000
Q3 2020 Nov 06, 2020	SELL	$13.67 - $17.77 $16,212 - $21,075	-1,186 Reduced 3.52%	32,512 $481,000
Q2 2020 Aug 05, 2020	BUY	$10.89 - $21.47 $117,764 - $232,176	10,814 Added 47.26%	33,698 $496,000
Q1 2020 May 12, 2020	BUY	$10.23 - $24.56 $16,081 - $38,608	1,572 Added 7.38%	22,884 $269,000
Q4 2019 Feb 05, 2020	BUY	$17.42 - $26.61 $175,401 - $267,936	10,069 Added 89.56%	21,312 $501,000
Q3 2019 Nov 13, 2019	BUY	$16.36 - $21.39 $183,935 - $240,487	11,243 New	11,243 $208,000
Q2 2019 Aug 12, 2019	SELL	$16.93 - $26.22 $157,618 - $244,108	-9,310 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$23.15 - $28.34 $3,287 - $4,024	142 Added 1.55%	9,310 $228,000
Q4 2018 Feb 14, 2019	SELL	$22.03 - $32.01 $66,993 - $97,342	-3,041 Reduced 24.91%	9,168 $238,000
Q3 2018 Nov 14, 2018	SELL	$30.0 - $40.85 $80,790 - $110,009	-2,693 Reduced 18.07%	12,209 $386,000
Q2 2018 Aug 13, 2018	BUY	$26.4 - $42.0 $393,412 - $625,884	14,902 New	14,902 $0

Others Institutions Holding HRTX

# of Institutions

174

Shares Held

121M

Call Options Held

80.4K

Put Options Held

94.9K

View Full List

About HERON THERAPEUTICS, INC.

Ticker HRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,774,000
Market Cap $220M
Description
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...

More about HRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account

Principal Financial Group Inc Heron Therapeutics, Inc. Transaction History